CA3217856A1 - Heterocyclic compounds and methods of use - Google Patents
Heterocyclic compounds and methods of use Download PDFInfo
- Publication number
- CA3217856A1 CA3217856A1 CA3217856A CA3217856A CA3217856A1 CA 3217856 A1 CA3217856 A1 CA 3217856A1 CA 3217856 A CA3217856 A CA 3217856A CA 3217856 A CA3217856 A CA 3217856A CA 3217856 A1 CA3217856 A1 CA 3217856A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- fluorotetrahydro
- pyrrolizin
- diazabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181625P | 2021-04-29 | 2021-04-29 | |
| US63/181,625 | 2021-04-29 | ||
| US202163277309P | 2021-11-09 | 2021-11-09 | |
| US63/277,309 | 2021-11-09 | ||
| PCT/US2022/026623 WO2022232331A1 (en) | 2021-04-29 | 2022-04-28 | Heterocyclic compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217856A1 true CA3217856A1 (en) | 2022-11-03 |
Family
ID=83847330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217856A Pending CA3217856A1 (en) | 2021-04-29 | 2022-04-28 | Heterocyclic compounds and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250059205A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329757A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517695A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022264784A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3217856A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012726A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232331A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| CN115141215B (zh) * | 2021-03-30 | 2023-09-15 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2023125627A1 (en) * | 2021-12-28 | 2023-07-06 | Lynk Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound and application thereof |
| WO2023138583A1 (zh) * | 2022-01-21 | 2023-07-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023198191A1 (zh) * | 2022-04-15 | 2023-10-19 | 杭州多域生物技术有限公司 | 一种六元并六元化合物、制备方法、药物组合物和应用 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202400600A (zh) * | 2022-06-16 | 2024-01-01 | 美商昂勝醫療科技股份有限公司 | 喹唑啉衍生物、其組成物及方法 |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| WO2024046370A1 (zh) * | 2022-08-30 | 2024-03-07 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物,及其制备和治疗用途 |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| US20250059208A1 (en) * | 2023-06-30 | 2025-02-20 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN122374018A (zh) | 2023-10-06 | 2026-07-10 | 美国安进公司 | 用于癌症治疗的组合疗法 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104321322A (zh) * | 2012-03-30 | 2015-01-28 | 理森制药股份公司 | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 |
| US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10544099B2 (en) * | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| US20200352931A1 (en) * | 2017-12-12 | 2020-11-12 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| WO2020097537A2 (en) * | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| CN112110918B (zh) * | 2019-06-21 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物,其制法与医药上的用途 |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4144732A4 (en) * | 2020-04-29 | 2024-05-01 | Shanghai Ringene BioPharma Co., Ltd. | BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| AU2022220678A1 (en) * | 2021-02-09 | 2023-09-21 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| JP2024505594A (ja) * | 2021-02-09 | 2024-02-06 | メッドシャイン ディスカバリー インコーポレイテッド | ピリミジン芳香環化合物 |
| MX2023008463A (es) * | 2021-02-16 | 2023-12-07 | Leidos Biomedical Res Inc | Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras). |
| KR20230169967A (ko) * | 2021-03-12 | 2023-12-18 | 브리스톨-마이어스 스큅 컴퍼니 | Kras g12d 억제제 |
| WO2022192790A1 (en) * | 2021-03-12 | 2022-09-15 | Bristol-Myers Squibb Company | Kras inhibitors |
| EP4329888A1 (en) * | 2021-04-29 | 2024-03-06 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
-
2022
- 2022-04-28 WO PCT/US2022/026623 patent/WO2022232331A1/en not_active Ceased
- 2022-04-28 MX MX2023012726A patent/MX2023012726A/es unknown
- 2022-04-28 JP JP2023565518A patent/JP2024517695A/ja active Pending
- 2022-04-28 EP EP22796686.8A patent/EP4329757A4/en active Pending
- 2022-04-28 AU AU2022264784A patent/AU2022264784A1/en active Pending
- 2022-04-28 CA CA3217856A patent/CA3217856A1/en active Pending
- 2022-04-28 US US18/696,946 patent/US20250059205A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022232331A1 (en) | 2022-11-03 |
| EP4329757A4 (en) | 2025-03-26 |
| MX2023012726A (es) | 2024-01-04 |
| JP2024517695A (ja) | 2024-04-23 |
| EP4329757A1 (en) | 2024-03-06 |
| US20250059205A1 (en) | 2025-02-20 |
| AU2022264784A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12570672B2 (en) | Macrocyclic compounds and methods of use | |
| US20250059205A1 (en) | Heterocyclic Compounds and Methods of Use | |
| TW202321242A (zh) | 雜環化合物及使用方法 | |
| US20250179077A1 (en) | Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins | |
| CA3228310A1 (en) | Heterocyclic compounds and methods of use | |
| CA3217830A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| TW202317566A (zh) | 雜環化合物及使用方法 | |
| AU2023477424A1 (en) | Indazole containing compounds and methods of use | |
| WO2024138206A1 (en) | Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof | |
| WO2025194057A1 (en) | Macrocyclic compounds as modulators of kras and uses thereof | |
| IL288672B1 (en) | Tricyclic compounds and their use | |
| CN117561063A (zh) | 杂环化合物及使用方法 | |
| US20250034167A1 (en) | Heterocyclic compounds and methods of use | |
| CN117897159A (zh) | 杂环化合物及使用方法 | |
| CN117835976A (zh) | 杂环化合物及使用方法 | |
| CN117881397A (zh) | 杂环化合物及使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250912 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260320 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260320 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260415 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260420 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260420 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260420 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260420 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260420 |